Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.

Participants needed: 146
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Toray Industries, IncUpdated: Jun 23, 2026Locations: 27
Eligibility criteria

Histologically or cytologically confirmed metastatic, or locally advanced and un... [+13]

Prior history of treatment with ramucirumab or paclitaxel. [+18]

Read more
Status: Recruiting

A Study of TRK-950 in Patients With Advanced Solid Tumors

Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists

Participants needed: 49
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Toray Industries, IncUpdated: Apr 13, 2026Locations: 10
Eligibility criteria

Part 1: Patients with histologically and cytologically confirmed locally advance... [+5]

Patients with active, uncontrolled bacterial, viral, or fungal infection requiri... [+6]

Read more
Status: Recruiting

Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)

The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).

Participants needed: 45
Trial details
Age: 16+Biological sex: AllType: InterventionalSponsor: Toray Industries, IncUpdated: Jul 9, 2024Locations: 1
Eligibility criteria

Patients within 7 days from invasion or exacerbation of respiratory symptoms or... [+10]

Patients who are considered to be extremely unlikely to withdraw from mechanical... [+46]

Read more